Leticia Goncalves Lourenco
CIK 1974509 · View on SEC EDGAR ↗
First SEC filing: Feb. 6, 2025 · Latest: Feb. 6, 2025
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | IFF | M | 4,305 | — | — | 4,305 Direct | — | Acquired | (price as of 2026-08-21) |
| April 1, 2026 | IFF | M | 3,013 | — | — | 7,318 Direct | +69.99% | Acquired | (price as of 2026-08-21) |
| April 1, 2026 | IFF | F | 1,335 | $72.57 | $96,881 | 5,983 Direct | -18.24% | Disposed | 16.2% (price as of 2026-08-21) |
| April 1, 2026 | IFF | F | 1,908 | $72.57 | $138,464 | 4,075 Direct | -31.89% | Disposed | 16.2% (price as of 2026-08-21) |
| April 1, 2026 | IFF | A | 13,780 | — | — | 35,735 Direct | +62.76% | Acquired | (price as of 2026-08-21) |
| April 1, 2026 | IFF | M | 3,013 | $72.57 | $218,653 | 32,722 Direct | -8.43% | Disposed | 16.2% (price as of 2026-08-21) |
| April 1, 2026 | IFF | M | 4,305 | $72.57 | $312,414 | 28,417 Direct | -13.16% | Disposed | 16.2% (price as of 2026-08-21) |
| April 1, 2025 | IFF | A | 21,955 | — | — | 21,955 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 4, 2025 | EMR | A | 1,476 | — | — | 4,762 Direct | +44.92% | Acquired | (price as of 2026-08-21) |
| Feb. 6, 2024 | EMR | A | 1,867 | — | — | 3,286 Direct | +131.57% | Acquired | (price as of 2026-08-21) |
| May 2, 2023 | EMR | A | 1,419 | — | — | 1,419 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| April 1, 2026 | IFF | Restricted Stock Units | Common Stock (13,780) | — | — | 13,780 | Acquired |
| April 1, 2026 | IFF | Restricted Stock Units | Common Stock (3,013) | — | — | 3,013 | Disposed |
| April 1, 2026 | IFF | Restricted Stock Units | Common Stock (4,305) | — | — | 4,305 | Disposed |
| April 1, 2025 | IFF | Restricted Stock Units | Common Stock (21,955) | — | — | 21,955 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
IFF
President, Health & Biosciences| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $566,667 | $1,000,000 | — | — | $600,372 | $232 | $45,120 | $5,809,059 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.